Autolus Therapeutics plc (F:6A3A) — Stock Price
Autolus Therapeutics plc (F:6A3A) is currently trading at €1.79 EUR, up 4.68% today. Over the past 52 weeks, shares have ranged between €1.06 and €2.10. This page tracks Autolus Therapeutics plc's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market cap of Autolus Therapeutics plc.
Autolus Therapeutics plc (6A3A) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Autolus Therapeutics plc's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
Autolus Therapeutics plc Income Statement — Revenue, Profit & Earnings by Year
Autolus Therapeutics plc's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €75.39 Million | €10.12 Million | €1.70 Million | €6.19 Million | €2.33 Million |
| Cost of Revenue | €96.37 Million | €11.39 Million | €0.00 | — | — |
| Gross Profit | €-20.98 Million | €-1.27 Million | €1.70 Million | — | — |
| Research & Development | €117.69 Million | €138.44 Million | €130.48 Million | €141.99 Million | €134.79 Million |
| SG&A | €131.87 Million | €101.72 Million | €46.74 Million | €31.90 Million | €31.86 Million |
| Total Operating Expenses | €345.93 Million | €251.55 Million | €177.23 Million | €173.72 Million | €166.65 Million |
| Operating Income | €-270.54 Million | €-241.43 Million | €-175.53 Million | €-167.53 Million | €-164.32 Million |
| EBITDA | — | — | — | €-156.88 Million | €-156.43 Million |
| EBIT | — | — | — | €-167.53 Million | €-164.32 Million |
| Interest Expense | €36.67 Million | €9.29 Million | €45.07 Million | €8.90 Million | €1.10 Million |
| Income Before Tax | €-285.56 Million | €-219.13 Million | €-208.40 Million | €-173.21 Million | €-165.99 Million |
| Income Tax Expense | — | — | — | €-24.37 Million | €-23.89 Million |
| Net Income | €-287.53 Million | €-220.66 Million | €-208.38 Million | €-148.84 Million | €-142.10 Million |
Autolus Therapeutics plc Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Autolus Therapeutics plc's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €589.07 Million | €782.73 Million | €375.38 Million | €490.27 Million | €405.56 Million |
| Total Current Assets | €435.92 Million | €660.93 Million | €275.30 Million | €425.77 Million | €346.95 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €196.58 Million | €360.64 Million | €0.00 | — | — |
| Net Receivables | €24.02 Million | €15.00K | €109.00K | €121.00K | €26.25 Million |
| Inventory | €33.21 Million | €4.14 Million | €0.00 | — | — |
| Property, Plant & Equipment | — | — | — | €58.42 Million | €52.32 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €410.94 Million | €355.40 Million | €263.91 Million | €191.60 Million | €92.24 Million |
| Total Current Liabilities | €73.44 Million | €60.74 Million | €44.74 Million | €46.37 Million | €28.55 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | €178.13 Million | €427.32 Million | €111.47 Million | €298.67 Million | €313.32 Million |
| Retained Earnings | €-1.39 Billion | €-1.10 Billion | €-878.56 Million | €-670.18 Million | €-521.34 Million |
Autolus Therapeutics plc Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Autolus Therapeutics plc generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-283.57 Million | €-206.27 Million | €-145.59 Million | €-112.31 Million | €-117.86 Million |
| Capital Expenditures | €27.13 Million | €34.82 Million | €10.99 Million | €10.84 Million | €8.86 Million |
| Free Cash Flow | €-310.70 Million | €-241.09 Million | €-156.57 Million | €-123.15 Million | €-126.72 Million |
| Investing Cash Flow | — | — | — | €-10.84 Million | €-8.86 Million |
| Financing Cash Flow | €-4.34 Million | €589.55 Million | €-883.00K | €223.61 Million | €284.06 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €14.44 Million | €15.47 Million | €11.20 Million | €12.01 Million | €9.94 Million |
| Depreciation | €9.81 Million | €7.72 Million | €6.57 Million | €7.36 Million | €8.37 Million |
| Change in Cash | €-123.17 Million | €-11.53 Million | €-142.43 Million | €72.08 Million | €156.59 Million |
Autolus Therapeutics plc Earnings History — EPS Actual vs. Analyst Estimates
Track Autolus Therapeutics plc's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 07, 2026 | — | -0.26 | — |
| Mar 19, 2026 | — | -0.43 | — |
| Nov 12, 2025 | — | -0.23 | — |
| Aug 08, 2025 | — | — | — |
| May 08, 2025 | — | — | — |
| Nov 03, 2022 | -0.47 | -0.46 | -2.17% |
| Aug 04, 2022 | -0.46 | -0.42 | -9.52% |
| May 04, 2022 | -0.41 | -0.48 | +14.58% |